β-Amyloid (1-42), rat

β-Amyloid (1-42), rat is a synthetic peptide corresponding to the 1-42 amino acid sequence of the rat amyloid beta protein. As a key fragment derived from the amyloid precursor protein (APP), it possesses a central role in neurodegenerative disease research, particularly in the context of amyloid aggregation and plaque formation. Structurally, the peptide is characterized by its propensity to form β-sheet-rich fibrils, making it a relevant tool for modeling amyloidogenic processes in vitro and in vivo. Its sequence homology to the endogenous rat peptide allows for species-specific investigations, supporting the development of mechanistic insights into protein misfolding, aggregation, and neurotoxicity pathways that underpin neurological disorders.

Neurodegeneration modeling: The peptide is widely utilized in the establishment of cellular and animal models of amyloid pathology. Researchers employ β-Amyloid (1-42), rat to induce amyloid plaque formation and neurotoxic effects that mirror those observed in age-related neurodegenerative diseases. Such models are instrumental for dissecting the molecular events leading to neuronal dysfunction, synaptic loss, and cognitive decline, providing a robust experimental system for hypothesis-driven studies of disease mechanisms.

Protein aggregation studies: Due to its intrinsic aggregation propensity, the peptide serves as a benchmark substrate in investigations of amyloid fibrillogenesis. Scientists use it to analyze the kinetics of oligomer and fibril formation, evaluate the influence of environmental conditions on aggregation, and assess the structural properties of amyloid assemblies. These studies contribute to a deeper understanding of the physicochemical principles governing protein misfolding and aggregation, which are central to amyloid-related pathologies.

Screening of aggregation modulators: The rat β-amyloid (1-42) peptide is a critical reagent in high-throughput screening assays designed to identify compounds that modulate amyloid aggregation. By providing a reproducible substrate for in vitro aggregation assays, it enables the evaluation of small molecules, peptides, or antibodies for their capacity to inhibit or promote fibril formation. Such screening efforts are foundational for the discovery and characterization of aggregation inhibitors with potential translational relevance in neurodegenerative disease research.

Biophysical and structural analysis: The peptide is frequently employed in studies utilizing techniques such as nuclear magnetic resonance (NMR), circular dichroism (CD) spectroscopy, and electron microscopy to elucidate the conformational dynamics and ultrastructural features of amyloid assemblies. These biophysical investigations shed light on the molecular architecture of oligomeric and fibrillar species, offering key insights into the relationship between peptide structure, aggregation state, and cytotoxicity.

Immunological assay development: β-Amyloid (1-42), rat is also used as a standard or antigen in the development and validation of immunoassays, including enzyme-linked immunosorbent assays (ELISA) and Western blotting protocols. Its defined sequence and aggregation profile make it suitable for generating calibration curves, assessing antibody specificity, and quantifying amyloid species in biological samples. Such applications are essential for advancing biomarker discovery and monitoring disease-relevant amyloid dynamics in experimental systems.

1. Uncarboxylated osteocalcin decreases insulin-stimulated glucose uptake without affecting insulin signaling and regulators of mitochondrial biogenesis in myotubes

2. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

3. The spatiotemporal control of signalling and trafficking of the GLP-1R

4. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

5. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate